Fig. 9

In vivo, the YAP inhibitor VP reverses the protective effect of Gap19 against the pathological process of ICH injury. a, b Representative photos of LFB staining showing that the volume of cerebral hematoma in the TAT-Gap19 + ICH + VP group was increased compared with that in the TAT-Gap19 + ICH group and that VP reversed the protective effect of Gap19 against white matter damage after ICH. c–f The mNSSs, balance beam scores, foot fault rates, and forelimb grip strength of mice treated with the YAP inhibitor VP were evaluated and statistically analyzed. The represent the SEM of the data from 6 samples per group. *P < 0.05, **P < 0.01 compared to the sham group. #P < 0.05, ##P < 0.01 compared with the TAT-Gap19 + ICH group